Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial.
Saved in:
| Title: | Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial. |
|---|---|
| Authors: | Heier JS; Ophthalmic Consultants of Boston, Boston, MA, USA. jsheier@eyeboston.com., Zhang X; Bayer Consumer Care AG, Basel, Switzerland., Reed K; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Berliner A; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Leal S; Bayer Consumer Care AG, Basel, Switzerland. |
| Source: | Eye (London, England) [Eye (Lond)] 2025 Jan 13. Date of Electronic Publication: 2025 Jan 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39805961 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Heier+JS%22">Heier JS</searchLink>; Ophthalmic Consultants of Boston, Boston, MA, USA. jsheier@eyeboston.com.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; Bayer Consumer Care AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Reed+K%22">Reed K</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Berliner+A%22">Berliner A</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Leal+S%22">Leal S</searchLink>; Bayer Consumer Care AG, Basel, Switzerland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228703986%22">Eye (London, England)</searchLink> [Eye (Lond)] 2025 Jan 13. <i>Date of Electronic Publication: </i>2025 Jan 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8703986 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5454 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220950222X%22">0950222X </searchLink><i>NLM ISO Abbreviation: </i>Eye (Lond) <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39805961 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41433-024-03543-x Languages: – Code: eng Text: English Titles: – TitleFull: Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Heier JS – PersonEntity: Name: NameFull: Zhang X – PersonEntity: Name: NameFull: Reed K – PersonEntity: Name: NameFull: Berliner A – PersonEntity: Name: NameFull: Leal S IsPartOfRelationships: – BibEntity: Dates: – D: 13 M: 01 Text: 2025 Jan 13 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1476-5454 Titles: – TitleFull: Eye (London, England) Type: main |
| ResultId | 1 |
